1. Hengst JCD, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res 40: 2135–2141
2. Ray PK, Raychaudhuri S (1981) Low-dose cyclophosphamide inhibition of transplantable fibrosarcoma growth by augmentation of the host immune response. J Natl Cancer Inst 67: 1341–1345
3. Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163–2167
4. El-Sady E, Parker D, Turk JL (1986) The effect of cyclophosphamide in vivo on the expression of lymphocyte markers, detected by monoclonal antibodies, in the rat. Int J Immunopharmacol 8: 961–966
5. Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4’ suppressor T-cells. Cancer Res 49: 1649–1654